Compare Dow Jones Industrial Average ETF (DIA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Pfizer Inc — how do they compare? Dow Jones Industrial Average ETF trades at $512.07 (market cap $45.20B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 3.5× Dow Jones Industrial Average ETF's market cap, and Pfizer Inc pays a 6.14% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Pfizer Inc for 158 Days on average.
| DIA | PFE | |
|---|---|---|
Market Cap | $45.20B | $159.59B |
Volume | 4,095,368 | 30,937,010 |
52-Week High | $542.79 | $29.02 |
52-Week Low | $451.37 | $23.67 |
Typical Hold Time | 103 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $511.02, down 0.68% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent dividend distributions provide income appeal, though key valuation metrics remain unavailable. Support levels cluster around $506-509 while resistance sits at $512-516.
The ETF faces near-term headwinds from technical weakness and broader market volatility. Dividend payments offer income stability, but lack of fundamental metrics limits valuation assessment. Market sentiment remains cautious amid economic uncertainty and Fed policy concerns.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
